{"id":"NCT03703310","sponsor":"Sol-Gel Technologies, Ltd.","briefTitle":"Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)","officialTitle":"A Multicenter, Randomized, Double-blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-02-19","primaryCompletion":"2020-12-28","completion":"2020-12-28","firstPosted":"2018-10-11","resultsPosted":"2024-07-03","lastUpdate":"2024-07-03"},"enrollment":174,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Basal Cell Nevus Syndrome"],"interventions":[{"type":"DRUG","name":"Patidegib Topical Gel, 2%","otherNames":["IP"]},{"type":"DRUG","name":"Patidegib Topical Gel, Vehicle","otherNames":["IP, Vehicle"]}],"arms":[{"label":"Patidegib Topical Gel, 2%,","type":"EXPERIMENTAL"},{"label":"Patidegib Topical Gel, Vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"This is a global, multicenter, randomized, double-blind, stratified, vehicle-controlled study of the efficacy and safety of Patidegib Topical Gel, 2%, applied topically twice daily to the face of adult participants with Gorlin syndrome. Participants will be required to apply the investigational product for 12 months. The primary endpoint is a comparison between the two treatment arms of the number of new BCCs that develop over the 12 month period.","primaryOutcome":{"measure":"Number of New BCCs Per Participant","timeFrame":"Month 12","effectByArm":[{"arm":"Patidegib Topical Gel, 2%,","deltaMin":2.84,"sd":3.39},{"arm":"Patidegib Topical Gel, Vehicle","deltaMin":4.03,"sd":4.76}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":49,"countries":["United States","Belgium","Canada","Denmark","France","Germany","Italy","Netherlands","Spain","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":87},"commonTop":["Pruritus","Upper respiratory tract infection","Dry skin","Headache","Nasopharyngitis"]}}